Does Kisqali Require Regular EKG Monitoring?
Yes, Kisqali (ribociclib) requires regular EKG monitoring due to its risk of causing QT interval prolongation, which can lead to serious heart rhythm problems. The prescribing information recommends an EKG before starting treatment, on day 14 of cycle 1, at the start of cycle 2, and periodically afterward, especially if patients have risk factors like heart disease, electrolyte imbalances, or use of QT-prolonging drugs.[1]
What Triggers EKG Checks During Treatment?
EKGs are mandated at specific points: baseline (before cycle 1 day 1), day 14 of cycle 1, and day 1 of cycle 2. Repeat EKGs occur periodically or if symptoms like dizziness or palpitations appear. Labs for electrolytes (potassium, calcium, magnesium, phosphorus) must accompany these to manage QT risks.[1]
Why Does Kisqali Affect Heart Rhythm?
Kisqali, a CDK4/6 inhibitor for HR+/HER2- breast cancer, prolongs the QT interval by blocking cardiac potassium channels. Clinical trials showed grade 3/4 QT prolongation in 1-3% of patients, with higher rates in those on interacting drugs like certain antibiotics or antiemetics.[1][2]
Who Needs Extra Monitoring?
Patients over 65, those with cardiac history (e.g., bradycardia, heart failure), or on CYP3A inhibitors/inducers face higher risks. Avoid starting Kisqali if baseline QTc exceeds 450 ms (men) or 470 ms (women), or if it worsens during treatment.[1]
What Happens If QT Interval Prolongs?
Dose interruptions or reductions are required if QTc exceeds 481 ms or increases over 60 ms from baseline. Permanent discontinuation applies if it persists or causes life-threatening arrhythmias. No deaths from QT prolongation were reported in trials, but monitoring prevents complications.[1][2]
How Does This Compare to Verzenio or Ibrance?
Kisqali has stricter EKG rules than Ibrance (palbociclib), which lacks routine QT monitoring but warns of risks. Verzenio (abemaciclib) requires baseline EKGs but less frequent follow-up unless issues arise. All carry QT warnings, but Kisqali's label is most explicit.[1][3]
[1]: Kisqali Prescribing Information (Novartis)
[2]: FDA Label for Ribociclib
[3]: Drugs.com Comparison of CDK4/6 Inhibitors